Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Capital Employed (2021 - 2025)

Gain Therapeutics has reported Return on Capital Employed over the past 5 years, most recently at 2.82% for Q3 2025.

  • Quarterly results put Return on Capital Employed at 2.82% for Q3 2025, down 106.0% from a year ago — trailing twelve months through Sep 2025 was 2.82% (down 106.0% YoY), and the annual figure for FY2024 was 1.78%, down 42.0%.
  • Return on Capital Employed for Q3 2025 was 2.82% at Gain Therapeutics, up from 3.12% in the prior quarter.
  • Over the last five years, Return on Capital Employed for GANX hit a ceiling of 0.19% in Q2 2021 and a floor of 3.12% in Q2 2025.
  • Median Return on Capital Employed over the past 5 years was 1.57% (2023), compared with a mean of 1.42%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -151bps in 2023 and later surged 39bps in 2024.
  • Gain Therapeutics' Return on Capital Employed stood at 0.36% in 2021, then plummeted by -122bps to 0.8% in 2022, then plummeted by -142bps to 1.95% in 2023, then fell by -12bps to 2.18% in 2024, then dropped by -29bps to 2.82% in 2025.
  • The last three reported values for Return on Capital Employed were 2.82% (Q3 2025), 3.12% (Q2 2025), and 2.97% (Q1 2025) per Business Quant data.